Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3976
Rimini Street
RMNI
$445M
| $187K | ﹤0.01% |
53,796
-26,629
| -33% | -$86.3K |
|
3977
Coherus Oncology
CHRS
$181M
| $186K | ﹤0.01% |
230,990
-69,202
| -23% | -$79.6K |
|
|
ADAG
3978
Adagene
ADAG
$248M
| $186K | ﹤0.01% |
122,516
-64,387
| -34% | -$120K |
|
3979
Weyco Group
WEYS
$446M
| $186K | ﹤0.01% |
6,108
-2,998
| -33% | -$102K |
|
3980
Inhibrx
INBX
$1.44B
| $186K | ﹤0.01% |
13,283
-5,558
| -29% | -$75.5K |
|
|
SEPU
3981
AllianzIM U.S. Equity Buffer15 Uncapped Sep ETF
SEPU
$162M
| $186K | ﹤0.01% |
+7,432
| New | +$192K |
|
|
FVR
3982
FrontView REIT
FVR
$486M
| $185K | ﹤0.01% |
14,501
-7,202
| -33% | -$118K |
|
3983
Kodiak Sciences
KOD
$2.72B
| $184K | ﹤0.01% |
65,771
-8,156
| -11% | -$44.3K |
|
3984
Invesco S&P 500 Top 50 ETF
XLG
$10.9B
| $184K | ﹤0.01% |
4,000
| – | – |
|
3985
Inhibikase Therapeutics
IKT
$377M
| $184K | ﹤0.01% |
84,000
| – | – |
|
|
SVM
3986
Silvercorp Metals
SVM
$2.68B
| $184K | ﹤0.01% |
47,474
+1,779
| +4% | +$6.25K |
|
3987
Stereotaxis
STXS
$139M
| $183K | ﹤0.01% |
103,974
-9,065
| -8% | -$19.3K |
|
3988
Global X S&P 500 Quality Dividend ETF
QDIV
$30.7M
| $183K | ﹤0.01% |
5,200
+800
| +18% | +$28K |
|
|
AUGM
3989
FT Vest U.S. Equity Max Buffer ETF - August
AUGM
$31.8M
| $183K | ﹤0.01% |
5,758
+2,758
| +92% | +$88.2K |
|
|
XAPR
3990
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - April
XAPR
$29.7M
| $182K | ﹤0.01% |
5,554
+606
| +12% | +$19.8K |
|
3991
Ternium
TX
$10.8B
| $182K | ﹤0.01% |
5,850
+5,774
| +7,597% | +$175K |
|
3992
Symbotic
SYM
$5.35B
| $182K | ﹤0.01% |
9,014
+252
| +3% | +$6.44K |
|
3993
Aclaris Therapeutics
ACRS
$860M
| $182K | ﹤0.01% |
119,001
+103,800
| +683% | +$221K |
|
3994
FT Vest US Equity Enhance & Moderate Buffer ETF October
XOCT
$73.2M
| $182K | ﹤0.01% |
5,379
-457
| -8% | -$15.7K |
|
|
BLFY
3995
DELISTED
Blue Foundry Bancorp
BLFY
| $182K | ﹤0.01% |
19,767
-10,464
| -35% | -$100K |
|
|
PVBC
3996
DELISTED
Provident Bancorp
PVBC
| $182K | ﹤0.01% |
15,819
-7,756
| -33% | -$90.7K |
|
|
ZK
3997
DELISTED
Zeekr
ZK
| $180K | ﹤0.01% |
7,492
+386
| +5% | +$10.3K |
|
3998
Innovator US Equity Buffer ETF June
BJUN
$322M
| $180K | ﹤0.01% |
4,453
+667
| +18% | +$27.8K |
|
3999
Brookfield Renewable
BEP
$10.3B
| $180K | ﹤0.01% |
8,123
+125
| +2% | +$2.79K |
|
|
CRGX
4000
DELISTED
CARGO Therapeutics
CRGX
| $180K | ﹤0.01% |
44,193
-20,243
| -31% | -$136K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.